Reported Earlier, Revolution Medicines To Feature Zoldonrasib Phase 1 NSCLC And Daraxonrasib First-Line PDAC Data Among Nine Presentations At AACR Annual Meeting April 17-22 In San Diego

Benzinga Newsdesk www.benzinga.com Neutral 89.4%

Neg 0% Neu 89.4% Pos 0%

Comments

No comments yet. Be the first!